Stonepine Capital Management, LLC Quant / Systematic

CIK: 0001440771 · Show all filings

Period: Q1 2017 (← Previous) (Next →)

Filing Date: May 12, 2017

Total Value ($000): $177,452 (92.5% shares, 7.5% debt)

Holdings (21)

Recro Pharma, Inc. 14.2%
Value ($000) $25,122 Shares 2,874,317 Est. Cost $8.20 Unrealized
Viveve Medical, Inc 13.7%
Value ($000) $24,256 Shares 3,849,711 Est. Cost $6.92 Unrealized
Novelion Therapeutics, Inc. 9.4%
Value ($000) $16,760 Shares 1,560,487 Est. Cost $8.47 Unrealized
Sciclone Pharmaceuticals, Inc. 9.2%
Value ($000) $16,300 Shares 1,663,281 Est. Cost $10.55 Unrealized
Aegerion Pharmaceuticals, Inc. 7.5%
Value ($000) $13,280 Shares 16,600,000 Est. Cost $0.60 Unrealized
Ophthotech Corp 7.3%
Value ($000) $12,870 Shares 3,516,489 Est. Cost $4.42 Unrealized
Alere Inc. 6.2%
Value ($000) $10,926 Shares 275,000 Est. Cost $42.05 Unrealized
VCEL Vericel Corp 5.2%
Value ($000) $9,143 Shares 3,265,323 Est. Cost $2.65 Unrealized +6.6%
Cardiome Pharma Corp 4.7%
Value ($000) $8,299 Shares 2,757,260 Est. Cost $2.98 Unrealized
Avadel Pharmaceuticals PLC 4.1%
Value ($000) $7,283 Shares 752,410 Est. Cost $9.68 Unrealized
ENTA Enanta Pharmaceuticals 3.2%
Value ($000) $5,701 Shares 185,099 Est. Cost $28.66 Unrealized +8.6%
Biodelivery Sciences INTL 3.0%
Value ($000) $5,405 Shares 2,844,820 Est. Cost $1.76 Unrealized
VCYT Veracyte, Inc. 3.0%
Value ($000) $5,308 Shares 578,200 Est. Cost $7.48 Unrealized +9.4%
CPIX Cumberland Pharmaceuticals, Inc. 2.9%
Value ($000) $5,135 Shares 739,917 Est. Cost $5.11 Unrealized +18.6%
Alimera Sciences, Inc 2.0%
Value ($000) $3,607 Shares 2,576,273 Est. Cost $1.25 Unrealized
Durect Corporation 1.7%
Value ($000) $2,941 Shares 2,801,376 Est. Cost $1.30 Unrealized
Trinity Biotech PLC - SPON ADR 1.2%
Value ($000) $2,097 Shares 351,917 Est. Cost $6.92 Unrealized
EBS Emergent Biosolutions Inc 0.9%
Value ($000) $1,583 Shares 54,505 Est. Cost $30.44 Unrealized 0.0%
XOMA XOMA CORP 0.4%
Value ($000) $625 Shares 87,960 Est. Cost $5.14 Unrealized 0.0%
VNDA VANDA PHARMACEUTICALS INC 0.3%
Value ($000) $606 Shares 43,300 Est. Cost $14.25 Unrealized 0.0%
Aviragen Therapeutics, Inc. 0.1%
Value ($000) $205 Shares 314,421 Est. Cost $1.47 Unrealized